Drug Details
| General Information of the Drug (ID: DR4213) | ||||
|---|---|---|---|---|
| Name |
Raloxifene
|
|||
| Synonyms |
raloxifene; 84449-90-1; Keoxifene; Evista; Raloxifenum [Latin]; Raloxifeno [Spanish]; Raloxifenum; Raloxifeno; LY 139481; LY-139481; UNII-YX9162EO3I; Optruma; CHEMBL81; Keoxifene; LY 139481;; CHEBI:8772; YX9162EO3I; RAL; LY139481; CCRIS 7129; HSDB 7460; NCGC00015889-05; CAS-82640-04-8; Pharoxifene; Raloxifene D4; Raloxifene, 6; Raloxifene (INN); Eviden (TN); Raxeto (TN); Lopac-R-1402; DSSTox_CID_3550; SCHEMBL6144; DSSTox_RID_77076; DSSTox_GSID_23550; Lopac0_001051; BSPBio_000903; KBioGR_002361; KBioSS_002364; BIDD:ER0216; BIDD:GT0795; SPBio_002824; BPBio1_000995; GTPL2820; DTXSID3023550; BDBM19441; KBio2_002361; KBio2_004929; KBio2_007497; KBio3_002840; cid_11071264; cMAP_000032; HMS2089F06; HMS3742O11; ZINC538275; BCP09772; Tox21_202603; MFCD00866415; NSC747974; NSC761389; s5781; AKOS015896267; AC-8399; CCG-205128; DB00481; MCULE-4598311006; NSC-747974; NSC-761389; SDCCGSBI-0051021.P003; MRF-0000684; SMP2_000095; AS-35086; HY-13738; J22.982B; SBI-0051021.P002; AB0073011; CAS-84449-90-1; CS-0007764; FT-0674305; VU0155042-3; C07228; D08465; 449R901; Q425223; BRD-K63828191-003-11-5;
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Osteoporosis [ICD-11: FB83] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C28H27NO4S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
|
|||
| InChI |
1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
|
|||
| InChIKey |
GZUITABIAKMVPG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 84449-90-1
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells. | |||||
| Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of Res and Ral via increased expression of apoptotic genes including Bax, p53 and caspase-3 and caspase-8 is able to promote apoptosis as a mitochondrial dependent pathway in MCF7 and MDA-MB-231. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Estrogen receptor (ESR) | Molecule Info | [4] | |
| KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Prolactin signaling pathway | |||
| 3 | Thyroid hormone signaling pathway | |||
| 4 | Endocrine and other factor-regulated calcium reabsorption | |||
| 5 | Proteoglycans in cancer | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| 2 | EGFR1 Signaling Pathway | |||
| 3 | RANKL Signaling Pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Signaling events mediated by HDAC Class II | |||
| 3 | Plasma membrane estrogen receptor signaling | |||
| 4 | LKB1 signaling events | |||
| 5 | Regulation of Telomerase | |||
| 6 | ATF-2 transcription factor network | |||
| 7 | AP-1 transcription factor network | |||
| 8 | FOXM1 transcription factor network | |||
| 9 | Validated nuclear estrogen receptor alpha network | |||
| 10 | Signaling mediated by p38-alpha and p38-beta | |||
| 11 | FOXA1 transcription factor network | |||
| Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
| 2 | Nuclear Receptor transcription pathway | |||
| WikiPathways | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Estrogen Receptor Pathway | |||
| 4 | Signaling by ERBB4 | |||
| 5 | JAK/STAT | |||
| 6 | Integrated Pancreatic Cancer Pathway | |||
| 7 | Leptin signaling pathway | |||
| 8 | miR-targeted genes in muscle cell - TarBase | |||
| 9 | Integrated Breast Cancer Pathway | |||
| 10 | Nuclear Receptors | |||
